Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

• click to rate

  Posted by Two Blokes May 14 - Filed in Stock - 6 views
  
  Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago.